The isoproterenol-induced myocardial fibrosis: A biochemical and histological investigation

Biomed Pharmacother. 2024 May:174:116534. doi: 10.1016/j.biopha.2024.116534. Epub 2024 Apr 1.

Abstract

The isoproterenol (ISO)-induced myocardial fibrosis is considered a reliable and repeatable experimental model characterized by a relatively low mortality rate. Although is well-known that ISO stimulates the β1 adrenergic receptors at the myocardial level, a high degree of heterogeneity emerges around the doses and duration of the treatment generating unclear results. Therefore, we propose to gain insights into the progression of ISO-induced myocardial fibrosis, in order to critically analyze and optimize the experimental model. Male Wistar rats (12-14-week-old) were submitted to subcutaneous injection of ISO, in particular, two doses were selected: the commonly used dose of 5 mg/kg and a lower dose of 1 mg/kg, administered for 3 and 6 days. Biochemical and histological examinations were conducted either immediately after the last administration or after a recovering period of 7 or 14 days from the initial administration. Noteworthy, from our investigation emerged that even the lower dose of ISO was able to induce the maximal biochemical and histological alterations, suggesting that lower doses should be considered to control the progression of the damage more precisely and to identify a prodromic phase in which intervention with pharmacological or nutraceutical tools can be effectively attempted.

Keywords: Cardiac fibrosis; Cardiac remodeling; Heart failure; Isoproterenol; Scar.

MeSH terms

  • Animals
  • Cardiomyopathies / chemically induced
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / pathology
  • Cardiomyopathies / prevention & control
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Fibrosis*
  • Isoproterenol*
  • Male
  • Myocardium* / metabolism
  • Myocardium* / pathology
  • Rats
  • Rats, Wistar*

Substances

  • Isoproterenol